Cy Biopharma

Cy Biopharma AG is a Swiss biotech company developing novel psilocybin-derived small molecule therapies for chronic pain and other CNS conditions, with a focus on rare and orphan indications. Operating from Baar, Switzerland, Cy screens biochemical extracts combined with serotonin receptor agonists to create new molecular entities, and has formed a strategic supply and collaboration partnership with Australian life sciences company Bioxyne Limited for Australasia and global markets.